<DOC>
	<DOCNO>NCT02924766</DOCNO>
	<brief_summary>The purpose study assess safety pharmacokinetics niraparib administer combination apalutamide men metastatic castration resistant prostate cancer ( mCRPC ) may may deoxyribonucleic acid ( DNA ) -repair anomaly .</brief_summary>
	<brief_title>A Safety Pharmacokinetics Study Niraparib Plus Apalutamide Men With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<criteria>Greater ( &gt; ) 18 year age ( high legal age consent jurisdiction study take place ) At least 1 line prior taxanebased chemotherapy At least 1 line prior Androgen Receptor ( AR ) target therapy Progression metastatic prostate cancer set castrate level testosterone less equal ( &lt; = ) 50 nanogram per deciliter ( ng/dL ) gonadotropin release hormone analog ( GnRHa ) , history bilateral orchiectomy study entry define one following : ( ) Prostate Specific Antigen ( PSA ) progression define minimum 2 rise PSA level interval great equal ( &gt; = ) 1 week determination . The PSA level screen visit &gt; =2 microgram per liter ( mcg/L ) [ 2 ng/mL ] , ( b ) Radiographic progression soft tissue bone disease Prostate Cancer Working Group 3 ( PCWG3 ) criterion Must continue gonadotropin release hormone analog ( GnRHa ) course study surgically castrate Prior treatment poly ( adenosine diphosphate [ ADP ] ribose ) polymerase ( PARP ) inhibitor Known history current diagnosis myelodysplastic syndrome ( MDS ) /acute myeloid leukemia ( AML ) Known symptomatic impending cord compression , except participant receive definitive treatment demonstrate evidence clinically stable disease Presence uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 160 millimeter mercury ( mmHg ) diastolic BP &gt; 100 mmHg ) . Participants history hypertension allow , provide BP control within limit antihypertensive treatment Current prior treatment antiepileptic medication treatment seizure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>